Coya Therapeutics (NASDAQ:COYA) Receives "Sell (D-)" Rating from Weiss Ratings

Key Points

• Coya Therapeutics has received a "Sell (D-)" rating from Weiss Ratings, reflecting concerns about its stock performance.
• Despite the sell rating, five other analysts have rated the stock as a Buy, with an average target price of $16.20.
• The company's recent earnings report showed a significant miss, with an EPS of ($0.36) compared to an expected ($0.22).

Coya Therapeutics (NASDAQ:COYA - Get Free Report)'s stock had its "sell (d-)" rating reaffirmed by equities research analysts at Weiss Ratings in a report released on Wednesday,Weiss Ratings reports.

Other analysts have also recently issued reports about the stock. Lake Street Capital started coverage on shares of Coya Therapeutics in a report on Wednesday, July 9th. They set a "buy" rating and a $16.00 target price for the company. Chardan Capital reaffirmed a "buy" rating and issued a $14.00 price objective on shares of Coya Therapeutics in a research note on Wednesday, September 17th. HC Wainwright reissued a "buy" rating and set a $18.00 target price on shares of Coya Therapeutics in a research note on Monday, August 25th. BTIG Research reissued a "buy" rating and set a $15.00 target price on shares of Coya Therapeutics in a research note on Tuesday, September 30th. Finally, D. Boral Capital reissued a "buy" rating and set a $18.00 target price on shares of Coya Therapeutics in a research note on Monday, September 29th. Five equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $16.20.

Coya Therapeutics Trading Down 1.2%

NASDAQ:COYA traded down $0.08 on Wednesday, reaching $6.32. The stock had a trading volume of 17,477 shares, compared to its average volume of 82,059. The company has a 50-day moving average of $6.11 and a 200 day moving average of $5.97. The stock has a market cap of $105.65 million, a P/E ratio of -5.09 and a beta of 0.19. Coya Therapeutics has a 12-month low of $4.65 and a 12-month high of $10.24.

Coya Therapeutics (NASDAQ:COYA - Get Free Report) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.14). The company had revenue of $0.16 million for the quarter, compared to analysts' expectations of $0.78 million. On average, equities analysts predict that Coya Therapeutics will post -1.15 EPS for the current year.

Institutional Trading of Coya Therapeutics

Several institutional investors have recently made changes to their positions in COYA. Charles Schwab Investment Management Inc. acquired a new stake in shares of Coya Therapeutics during the 1st quarter valued at about $65,000. Northwestern Mutual Wealth Management Co. acquired a new position in Coya Therapeutics in the second quarter valued at about $119,000. Jane Street Group LLC boosted its position in Coya Therapeutics by 101.7% in the first quarter. Jane Street Group LLC now owns 26,137 shares of the company's stock valued at $169,000 after buying an additional 13,176 shares in the last quarter. Dauntless Investment Group LLC acquired a new position in Coya Therapeutics in the first quarter valued at about $1,083,000. Finally, CM Management LLC boosted its position in Coya Therapeutics by 25.0% in the first quarter. CM Management LLC now owns 200,000 shares of the company's stock valued at $1,294,000 after buying an additional 40,000 shares in the last quarter. 39.75% of the stock is currently owned by institutional investors and hedge funds.

About Coya Therapeutics

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.